Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.24 USD

39.24
1,175,687

-0.71 (-1.78%)

Updated Oct 1, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Halozyme (HALO) Beats on Q2 Earnings, Raises 2021 Guidance

by Zacks Equity Research

Halozyme (HALO) second-quarter earnings and sales beat estimates. The company raises 2021 guidance. Stock up.

Prothena (PRTA) Q2 Earnings Top Estimates, Pipeline in Focus

by Zacks Equity Research

Prothena's (PRTA) earnings for the second quarter of 2021 beat estimates. Its pipeline remains in focus as the company expects to receive milestone payments from partners.

Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut

by Zacks Equity Research

Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.

Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View

by Zacks Equity Research

Exelixis (EXEL) beats on both earnings and revenues in the second quarter. Both figures increase on a year-over-year basis.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, SNY's TBIO Buyout, FDA Updates

by Kinjel Shah

Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce Q2 results. FDA approves AstraZeneca's (AZN) lupus medicine, Saphnelo. Sanofi (SNY) to buy Translate Bio.

Regeneron (REGN) Q2 Earnings Beat, REGEN-COV Boosts Performance

by Zacks Equity Research

Regeneron (REGN) beats on Q2 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and significant contribution from REGEN-COV.

Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in Q2. The company also raises revenues guidance for the year. It plans to start a pivotal study on SRP-9001 next month. Stock up.

Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout

by Zacks Equity Research

Jazz Pharma's (JAZZ) product revenues grow in the second quarter on the back of strong demand for its new drugs and additional sales from drugs added with the acquisition of GW Pharmaceuticals.

Amgen (AMGN) Q2 Earnings Top, COVID-Led Sales Woes to Linger

by Zacks Equity Research

Amgen (AMGN) beats Q2 estimates for both earnings and sales. It expects the pandemic to continue to hurt sales growth in the second half of 2021.

ImmunoGen (IMGN) Q2 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates.

Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y

by Zacks Equity Research

Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.

AbbVie's (ABBV) Q2 Earnings In Line, 2021 Guidance Raised

by Zacks Equity Research

AbbVie (ABBV) matches second-quarter 2021 earnings estimates while beating the same for sales. Sales of new immunology drugs, Skyrizi and Rinvoq, reach $1 billion.

Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues

by Zacks Equity Research

Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.

TEVA Q2 Earnings Beat Estimates, Revenues Miss, Stock Up

by Zacks Equity Research

TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.

Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on any update related to guidance.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.

Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars

by Zacks Equity Research

Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.

Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.

AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS

by Zacks Equity Research

The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.

Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan

by Zacks Equity Research

Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.

Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

by Zacks Equity Research

The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.

Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.

Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study

by Zacks Equity Research

Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.

BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

by Zacks Equity Research

The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

Lilly's (LLY) Protomer Acquisition to Expand Diabetes Pipeline

by Zacks Equity Research

Lilly (LLY), which holds a 14% stake in private biotech company Protomer, acquires the remaining interest in it. The acquisition is set to expand Lilly's diabetes pipeline.